[Primary sclerosing cholangitis].

By A. Stiehl, C. Benz, P. Sauer. Der Internist, 2000

1,451 citations recorded by the source corpus.

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease, characterized by fibrosing inflammation and obliteration of intra and/or extrahepatic bile ducts. The disease belongs to the most common cholestatic diseases in adults and at present is diagnosed with increasing frequency. It is very often associated with ulcerative colitis. Patients with PSC have an increased incidence of bile duct carcinomas and those with ulcerative colitis also have an increased incidence of colonic carcinomas. Immunosuppressive treatment is little effective. Ursodeoxycholic acid (UDCA) has been shown to improve liver histology in PSC. The aim is to treat patients as early as possible to prevent progression to the advanced stages of the disease. During treatment with UDCA stenoses of major ducts may develop and early endoscopic dilatation is highly effective. In patients with endstage disease, UDCA is not effective and liver transplantation is indicated.

Subfields: Epidemiology, Hepatology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/78ed69b8d8ab6788881b33a963974d0c2b61152d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Robert F. Schwabe
2. M. Trauner

In Hepatology

1. Robert F. Schwabe
2. Le-xing Yu
3. S. Affò

Citations in the corpus

• EASL Clinical Practice Guidelines: management of cholestatic liver diseases. (2009, background): “Endoscopic retrograde cholangiopancreatography (ERCP) has been the gold standard in diagnosing PSC [86,87], but ERCP is associated with complications such as pancreatitis and sepsis [88].”
• Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. (2012, background): “Both diseases are considered complex genetic diseases, but the etiopathogenesis is still unknown [1,2].”
• The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer (2016, background): “PSC encompasses many changes in the PME that may drive cancer development, including increased cholangiocyte proliferation, inflammation, fibrosis, and in advanced stages, cirrhosis (186, 194, 195).”
• Primary sclerosing cholangitis - a comprehensive review. (2017, methodology): “months trial period of low-dose (13-15 mg/kg/day) UDCA prescription is utilized, whereby a decrease in ALP levels is used as the basis for potential long-term prescription (224).”